cipla

Nifty likely to see profit booking after rally; these 3 stocks could return 6-8%

The market is expected to cool off a bit in the near-term after the recent rally. It is advisable to stick to large-caps and quality mid-cap names

Pharma stocks poised for a bounceback; 3 bets for over 20% returns

In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said

Earnings estimates show Nifty could touch 12K by FY20; 15 stocks to watch

The S&P BSE Sensex lost over 1200 points while for the Nifty the cut was a little over 400 points or 3.7 percent since September 28.

Hold Cipla; target of Rs 510: ICICI Direct

ICICI Direct recommended hold rating on Cipla with a target price of Rs 510 in its research report dated November 06, 2018.

Cipla's subsidiary to acquire US-based Avenue Therapeutics for $215 mn

"At the first stage closing, InvaGen or its affiliates will acquire, through the issuance by Avenue of new shares, shares representing a 33.3 per cent stake in Avenue's capital stock on a fully diluted basis for USD 35 million," Cipla said in a regulatory filling.

Top 12 growth stocks with strong management you can bet on for 1 year

The Q2FY19 earnings season so far has been in line with the expectations. Strong results declared by IT companies, upbeat numbers from RIL and robust growth reported by the FMCG companies are indicative of sustained demand environment.

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of the retina) in AIDS patients and in prevention of cytomegalovirus (CMV) disease after organ transplant.

Market Headstart: Nifty likely to open flat; 3 stocks which could give 3-5% return

Trends on SGX Nifty indicate a negative opening for the broader index in India, a fall of 31 points or 0.29 percent. Nifty futures were trading around 10,591-level on the Singaporean Exchange.

Interview: How Cipla plans to bounce back after a weak Q2

In an interview with Moneycontrol, Kedar Upadhye, Global Chief Financial Officer of Cipla, talked about the company's strategy going forward.

Continue to see GST impact of restocking in India sales: Cipla

Umang Vohra, Cipla's Managing Director, said some of the tender businesses are growing 40 percent lower than last year.

Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings

Brokerages such as HSBC, Credit Suisse and Citi have downgraded the stock based on the company’s guidance ahead.

Cipla Consolidated September 2018 Net Sales at Rs 4,011.90 crore, Down 1.73% Q-o-Q.

Cipla Standalone September 2018 Net Sales at Rs 3,094.71 crore, up 0.96% Q-o-Q

Cipla Q2 profit falls 11% YoY at Rs 377 crore; posts weak operational show

The earnings before interest, taxes, depreciation and amortization (EBITDA) fell 13 percent year on year at Rs 702 crore from Rs 804 crore during the same quarter of last year.

Promoters raise stake in 74 companies from BSE 500; does it make them attractive?

Equity markets around the globe have been under pressure on account of trade war fears, interest rate hike and valuation concerns

Cipla gets USFDA nod for hypertension, cardiac drug

The company has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Metoprolol ER tablets in the strengths of 50mg, 100mg and 200mg, Cipla said in a BSE filing.

Cipla's arm completes acquisition of South Africa's Mirren

Cipla Medpro South Africa (Pty) Ltd has completed the acquisition of 100 percent stake in South African firm Mirren on October 22, 2018, Cipla said in a filing to BSE.

Hunting for value? These 10 expert picks are a buy after recent fall

Experts feel that investors sitting on cash should buy into markets in a scattered manner instead of making a lump sum payment.

FII View | Foreign investors cautious on India, pharma & consumption attractive: Steven Birch

According to the latest report by IMF, India is poised to grow at 7.4 percent in 2018 and 7.8 percent in 2019, making it the fastest growing economy among peers overtaking China.

Cipla Q2 PAT may dip 6.7% YoY to Rs. 390 cr: HDFC Securities

Net Sales are expected to increase by 8.8 percent Y-o-Y (up 12.7 percent Q-o-Q) to Rs. 4,440 crore, according to HDFC Securities.

Cipla Q2 PAT seen up 3% YoY to Rs. 450.4 cr: Sharekhan

Net Sales are expected to increase by 7.8 percent Y-o-Y (up 11.7 percent Q-o-Q) to Rs. 4,401.4 crore, according to Sharekhan.

Cipla Q2 PAT may dip 12.7% YoY to Rs. 368.9 cr: ICICI Direct

Net Sales are expected to decrease by 1 percent Y-o-Y (up 2.6 percent Q-o-Q) to Rs. 4,042.4 crore, according to ICICI Direct.

Market Headstart: Nifty likely to open flat; 3 stocks which could give 14-17% return

Trends on SGX Nifty indicate a negative opening for the broader index in India, a fall of 17.5 points or 0.17 percent. Nifty futures were trading around 10,282-level on the Singaporean Exchange.

Podcast | Stock picks of the day: Cipla among 3 stocks which could return 14-17%

We expect Nifty to mean revert towards critical moving averages which are placed around 10,700-10,800 levels (200-DEMA placed around 10,779).

Cipla stock gains nearly 2% on USFDA approval for anti-nausea drug

Cipla has received approval from US Food and Drug Administration for Palonosetron Hydrocholride injectable, which is available in strength of 0.25 mg/5ml.